
RPaul
Advertisement
Articles by RPaul



The second half of 2012 has not been kind to FDA. Last month, Secretary Hamburg was grilled by the House of Representatives for failing to follow-up on warning letters to the New England Compounding Center (NECC), now comes word that a U.S. District Court has ruled that a sales representative’s off-label promotion of a drug was protected speech.
Advertisement
Latest Updated Articles
Pharma 2012 LayoffsJanuary 9th 2013
More Troubles for FDADecember 6th 2012
Amid Flu Epidemic a Focus on Vaccine InnovationJanuary 30th 2013
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Putting Sustainability to Work in Pharma
2
Managing Global Trial Supply Risk: Expert Insights
3
Why Oral Solid Dosage Validation Is a Business Continuity Function, Not Just a Compliance Requirement
4
Technology Transfer: Success Drivers and Obstacles Explained
5